Navigation Links
TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
Date:6/5/2008

ORLANDO, Fla., June 5 /PRNewswire/ -- New research presented at the recent American Urological Association Conference by Urologist Joel L. Marmar, M.D., showed that among men who previously failed to achieve erections on Viagra, Levitra and Cialis type tablets, 40% achieved an erection sufficient for penetration during sexual intercourse after given a single dose of a novel treatment called TriMix gel.

The research involved forty two (42) men diagnosed with erectile dysfunction and various other conditions such as high blood pressure, high cholesterol, diabetes and removal of the prostate. The average age was 55. All trial participants had previously failed on Viagra, Levitra or Cialis type tablets.

Test results were documented using various methodologies such as penile buckling pressures, RigiScans (an instrument that documents penile rigidity) and Erection Hardness Scores (EHS). All test participants experienced some degree of tumescence or increased blood flow and 17 of the patients or 40%, experienced erections sufficient for penetration during sexual intercourse.

Typically, trimix compound in liquid form requires refrigeration and the patient must use a needle to self inject. TriMix gel does not require refrigeration and does not use a needle. It allows the patient to carry the medicine on his person at room temperature. More importantly, an ED patient would not have to use a needle to self inject before sexual intercourse.

Dr. Marmar stated, "Among a group of men who previously failed to achieve erections on Viagra, Levitra and Cialis type tablets, TriMix-gel demonstrated statistically significant greater Erection Hardness Scores. TriMix gel may offer ED patients an elegant alternative to penile injection."
For more information visit http://www.trimixgel.com

Contact

T.J. Harkins

TriMix Laboratories

Cherry Hill, NJ

856-428-7008 x11

TJ (at) TriMixgel (dot) com


'/>"/>
SOURCE TriMix Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
2. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
3. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
4. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
7. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
8. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
11. CureDMs Diabetes Therapy Achieves Major Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 The National University of Singapore ... analytics company, signed a Memorandum of Understanding (MOU) ... in the region. Under this ... and Technology (BIGHEART) at NUS and Holmusk will ... to healthcare IT and medical device development. These ...
(Date:3/27/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... toxicology and efficacy studies. The company is harnessing the ... protein, MAGE A, in an effort to find a ... After 4 weeks of treatment in transgenic mice, ... toxicity in a full toxicology report of various organs. ...
(Date:3/27/2017)... March 27, 2017  Sanderling Ventures, portfolio company, ... a division of Johnson & Johnson. Torax manufactures and ... treatment of gastro-esophageal reflux disease (GERD). The LINK ... technology and the procedure is currently available in ... Torax Medical was founded by Sanderling Ventures, Mayo ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... science and clinical practice of radiosurgery, announced today the publication of a ... registry established to standardize data collection from patients treated with stereotactic radiosurgery ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. Brian ... Medical doctors and PhD scientists will speak to the press on behalf of over ... of an independent vaccine safety commission. , WHERE: , Zenger Room, National Press ...
(Date:3/28/2017)... ORANGE, Calif. (PRWEB) , ... March 28, 2017 ... ... of its leading physicians, Paul Yost, will begin serving as new board chair ... earlier this month. Yost will serve the remainder of soon-to-be former chair Mark ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO ... found in power plant water and steam. , Chlorides and sulfates cause pitting ... leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive porcelain ... smile.” The National Association of Dental Laboratories (NADL) is informing dentists about the ... of when utilizing dental laboratories and technicians that create these veneers. , ...
Breaking Medicine News(10 mins):